Synergistic anticancer immunity in metastatic triple-negative breast cancer through an in situ amplifying Peptide-Drug Conjugate
Ha Rin Kim, Seong Jin Park, Young Seok Cho, Yoon Gun Ko et autres
kr, Éthiopie, us, pr (code pays fourni par la source)
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
Ha Rin Kim, Seong Jin Park, Young Seok Cho, Yoon Gun Ko et autres
kr, Éthiopie, us, pr (code pays fourni par la source)
Zulfikar Azam, Xiaojun Zhang, Riajul Wahab, Md. Mahedi Hasan et autres
Abstract Detecting ovarian cancer (OC) early using existing biomarkers, e.g., cancer antigen 125 (CA125), is challenging due to its ubiquitous expression in many tissues. Doppel, a prion-like protein, expresses in male reproductive organ but absent in female reproductive systems and healthy tissues, …
us, kr (code pays fourni par la source)
Ha Kyeong Lee, Byoungmo Kim, Seho Kweon, Jeong Uk Choi et autres
Abstract The development of anticancer therapeutics has two main objectives: enhancing efficacy and lowering toxicity. Given these goals, an antibody-drug conjugate (ADC), which delivers highly cytotoxic payloads to tumor tissue specifically, is one of the most favorable treatments. ADC is a growing …
kr (code pays fourni par la source)
Seong Jin Park, Seho Kweon, Moyo Knowledge Mudhibadhi, Ha Rin Kim et autres
Abstract Since the appearance of oxaliplatin, FOLFOX therapy is positioned as the standard of care for colorectal cancer (CRC). And after the advent of capecitabine, an oral prodrug of 5-FU, both FOLFOX and CAPOX remain the first-line treatment for local and advanced …
Éthiopie (code pays fourni par la source)
Byoungmo Kim, Ha Kyeong Lee, Youngro Byun, Seung Rim Hwang et autres
Abstract The difficulty of finding a biomarker that is both specific and ubiquitous in cancer presents a barrier to targeted drug delivery. Some tumor-associated antigens are also found in normal tissue and contribute to “on-target toxicities”. Tumors are also heterogenous and plastic …
kr (code pays fourni par la source)
Ha Rin Kim, Seong Jin Park, Moyo Knowledge Mudhibadhi, Jae Hee Park et autres
Abstract Although Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) is the most well-known tumor driver gene with the highest mutation rate in several types of cancer, there is no effective mutant KRAS targeting drug yet. Recent studies have reported that macropinocytosis can …
Éthiopie (code pays fourni par la source)
Seho Kweon, Yoo‐Seong Jeong, Yoon Gun Ko, Seung Woo Chung et autres
Abstract Conventional chemotherapy with maximum tolerated dose (MTD) has shown confident anti-cancer effect and when combined with targeted therapy, immunotherapy. Yet, understanding about how the MTD regimen is optimized has lacked due to its high tumor burdens. In this study, the oral …
kr, us (code pays fourni par la source)
Ha Kyeong Lee, Ruby Maharjan, Yeojin Jeon, Jeong Uk Choi et autres
Abstract Introduction: Approved angiogenesis inhibitors generally target certain growth factors or their receptors, which exist in both normal and cancerous cells; this results in suppression of cell-signaling pathways throughout the body and causes adverse effects. For this reason, there is a need …
kr (code pays fourni par la source)
Do Joon Park, K. G. Lee, H. W. Kihm, Youngro Byun et autres
We report on drastic changes in the near-field spectrum as it evolves into the far field in periodically corrugated metallic nanoslit arrays. The far-field spectral minimum is located exactly at the near-field spectral maximum, where a quasimonochromatic standing wave pattern is observed …
kr, de (code pays fourni par la source)
BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.
L'essentiel de l'actu tech du Burkina & d'Afrique, chaque semaine dans votre boîte mail.
Gratuit · sans spam · désinscription en un clic